Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Aliki-Eleni Farmaki is active.

Publication


Featured researches published by Aliki-Eleni Farmaki.


Nature Communications | 2013

A rare functional cardioprotective APOC3 variant has risen in frequency in distinct population isolates.

Ioanna Tachmazidou; George V. Dedoussis; Lorraine Southam; Aliki-Eleni Farmaki; Graham R. S. Ritchie; Dionysia K. Xifara; Angela Matchan; Konstantinos Hatzikotoulas; N W Rayner; Yuning Chen; Toni I. Pollin; O'Connell; Laura M. Yerges-Armstrong; Chrysoula Kiagiadaki; Kalliope Panoutsopoulou; Jeremy Schwartzentruber; Loukas Moutsianas; Emmanouil Tsafantakis; Chris Tyler-Smith; Gilean McVean; Yali Xue; Eleftheria Zeggini

Isolated populations can empower the identification of rare variation associated with complex traits through next generation association studies, but the generalizability of such findings remains unknown. Here we genotype 1,267 individuals from a Greek population isolate on the Illumina HumanExome Beadchip, in search of functional coding variants associated with lipids traits. We find genome-wide significant evidence for association between R19X, a functional variant in APOC3, with increased high-density lipoprotein and decreased triglycerides levels. Approximately 3.8% of individuals are heterozygous for this cardioprotective variant, which was previously thought to be private to the Amish founder population. R19X is rare (<0.05% frequency) in outbred European populations. The increased frequency of R19X enables discovery of this lipid traits signal at genome-wide significance in a small sample size. This work exemplifies the value of isolated populations in successfully detecting transferable rare variant associations of high medical relevance.


Nature Communications | 2014

A rare variant in APOC3 is associated with plasma triglyceride and VLDL levels in Europeans

Nicholas J. Timpson; Klaudia Walter; Josine L. Min; Ioanna Tachmazidou; Giovanni Malerba; So-Youn Shin; Lu Chen; Marta Futema; Lorraine Southam; Valentina Iotchkova; Massimiliano Cocca; Jie Huang; Yasin Memari; Shane McCarthy; Petr Danecek; Dawn Muddyman; Massimo Mangino; Cristina Menni; John Perry; Susan M. Ring; Amadou Gaye; George Dedoussis; Aliki-Eleni Farmaki; Paul R. Burton; Philippa J. Talmud; Giovanni Gambaro; Tim D. Spector; George Davey Smith; Richard Durbin; J. Brent Richards

The analysis of rich catalogues of genetic variation from population-based sequencing provides an opportunity to screen for functional effects. Here we report a rare variant in APOC3 (rs138326449-A, minor allele frequency ~0.25% (UK)) associated with plasma triglyceride (TG) levels (−1.43 s.d. (s.e.=0.27 per minor allele (P-value=8.0 × 10−8)) discovered in 3,202 individuals with low read-depth, whole-genome sequence. We replicate this in 12,831 participants from five additional samples of Northern and Southern European origin (−1.0 s.d. (s.e.=0.173), P-value=7.32 × 10−9). This is consistent with an effect between 0.5 and 1.5 mmol l−1 dependent on population. We show that a single predicted splice donor variant is responsible for association signals and is independent of known common variants. Analyses suggest an independent relationship between rs138326449 and high-density lipoprotein (HDL) levels. This represents one of the first examples of a rare, large effect variant identified from whole-genome sequencing at a population scale.


Nature Communications | 2014

Genetic characterization of Greek population isolates reveals strong genetic drift at missense and trait-associated variants

Kalliope Panoutsopoulou; Konstantinos Hatzikotoulas; Dionysia K. Xifara; Vincenza Colonna; Aliki-Eleni Farmaki; Graham R. S. Ritchie; Lorraine Southam; Arthur Gilly; Ioanna Tachmazidou; Segun Fatumo; Angela Matchan; Nigel W. Rayner; Ioanna Ntalla; Massimo Mezzavilla; Yuan Chen; Chrysoula Kiagiadaki; Eleni Zengini; Vasiliki Mamakou; Antonis Athanasiadis; Margarita Giannakopoulou; Vassiliki-Eirini Kariakli; Rebecca N. Nsubuga; Alex Karabarinde; Manjinder S. Sandhu; Gil McVean; Chris Tyler-Smith; Emmanouil Tsafantakis; Maria Karaleftheri; Yali Xue; George Dedoussis

Isolated populations are emerging as a powerful study design in the search for low-frequency and rare variant associations with complex phenotypes. Here we genotype 2,296 samples from two isolated Greek populations, the Pomak villages (HELIC-Pomak) in the North of Greece and the Mylopotamos villages (HELIC-MANOLIS) in Crete. We compare their genomic characteristics to the general Greek population and establish them as genetic isolates. In the MANOLIS cohort, we observe an enrichment of missense variants among the variants that have drifted up in frequency by more than fivefold. In the Pomak cohort, we find novel associations at variants on chr11p15.4 showing large allele frequency increases (from 0.2% in the general Greek population to 4.6% in the isolate) with haematological traits, for example, with mean corpuscular volume (rs7116019, P=2.3 × 10−26). We replicate this association in a second set of Pomak samples (combined P=2.0 × 10−36). We demonstrate significant power gains in detecting medical trait associations.


Nature Genetics | 2016

Discovery and refinement of genetic loci associated with cardiometabolic risk using dense imputation maps

Valentina Iotchkova; Jie Huang; John A. Morris; Deepti Jain; Caterina Barbieri; Klaudia Walter; Josine L. Min; Lu Chen; William Astle; Massimilian Cocca; Patrick Deelen; Heather Elding; Aliki-Eleni Farmaki; Christopher S. Franklin; Tom R. Gaunt; Albert Hofman; Tao Jiang; Marcus E. Kleber; Genevieve Lachance; Jian'an Luan; Giovanni Malerba; Angela Matchan; Daniel Mead; Yasin Memari; Ioanna Ntalla; Kalliope Panoutsopoulou; Raha Pazoki; John Perry; Fernando Rivadeneira; Maria Sabater-Lleal

Large-scale whole-genome sequence data sets offer novel opportunities to identify genetic variation underlying human traits. Here we apply genotype imputation based on whole-genome sequence data from the UK10K and 1000 Genomes Project into 35,981 study participants of European ancestry, followed by association analysis with 20 quantitative cardiometabolic and hematological traits. We describe 17 new associations, including 6 rare (minor allele frequency (MAF) < 1%) or low-frequency (1% < MAF < 5%) variants with platelet count (PLT), red blood cell indices (MCH and MCV) and HDL cholesterol. Applying fine-mapping analysis to 233 known and new loci associated with the 20 traits, we resolve the associations of 59 loci to credible sets of 20 or fewer variants and describe trait enrichments within regions of predicted regulatory function. These findings improve understanding of the allelic architecture of risk factors for cardiometabolic and hematological diseases and provide additional functional insights with the identification of potentially novel biological targets.


Metabolism-clinical and Experimental | 2013

Flaxseed oil does not affect inflammatory markers and lipid profile compared to olive oil, in young, healthy, normal weight adults

Meropi D. Kontogianni; Antonis Vlassopoulos; Alexandra Gatzieva; Aliki-Eleni Farmaki; Stergios Katsiougiannis; Demosthenes B. Panagiotakos; Nick Kalogeropoulos; Fotini N. Skopouli

OBJECTIVE Olive oil (OO) is a rich source of monounsaturated fat and bioactive components that exert strong anti-oxidant and anti-inflammatory properties. Flaxseed oil (FO) is rich in α-linolenic n-3 fatty acid (ALA), which also exhibits anti-inflammatory effects. This randomized, cross-over study aimed at exploring whether diets enrichment with FO could beneficially alter inflammatory markers and lipid profile, compared to OO, in a sample of normal weight, apparently healthy young adults. MATERIALS AND METHODS Participants were supplied with 15 mL/day of either FO or OO. Each intervention and the wash-out period lasted 6 weeks. Dietary, anthropometric and physical activity variables were recorded at the beginning and the end of each intervention. Serum biochemical and inflammatory markers were measured. Compliance to the intervention was evaluated by fatty acid analysis in erythrocytes. Repeated Measures ANOVA was used to assess the effect of the treatment. RESULTS Thirty seven participants completed the study. No difference between the two interventions was observed in adiponectin, TNF-α, high sensitivity-CRP or glucose levels and lipid profile. At the end of the FO period, participants exhibited significant reductions in total (-5.0%) and LDL-cholesterol (-6.7%) levels (all P<0.01). During the FO and the OO period serum adiponectin changes were significantly correlated with changes in erythrocyte %ALA (rs=0.34, P=0.007) and in erythrocyte %EPA (r(s)=0.47, P=0.01), respectively. CONCLUSIONS Daily consumption of FO did not confer any benefit in inflammatory or biochemical markers in normal weight young adults, who traditionally use olive oil as the main edible oil.


Nature Communications | 2017

Whole genome sequencing and imputation in isolated populations identify genetic associations with medically-relevant complex traits

Lorraine Southam; Arthur Gilly; Daniel Suveges; Aliki-Eleni Farmaki; Jeremy Schwartzentruber; Ioanna Tachmazidou; Angela Matchan; Nigel W. Rayner; Emmanouil Tsafantakis; Maria Karaleftheri; Yali Xue; George Dedoussis; Eleftheria Zeggini

Next-generation association studies can be empowered by sequence-based imputation and by studying founder populations. Here we report ∼9.5 million variants from whole-genome sequencing (WGS) of a Cretan-isolated population, and show enrichment of rare and low-frequency variants with predicted functional consequences. We use a WGS-based imputation approach utilizing 10,422 reference haplotypes to perform genome-wide association analyses and observe 17 genome-wide significant, independent signals, including replicating evidence for association at eight novel low-frequency variant signals. Two novel cardiometabolic associations are at lead variants unique to the founder population sequences: chr16:70790626 (high-density lipoprotein levels beta −1.71 (SE 0.25), P=1.57 × 10−11, effect allele frequency (EAF) 0.006); and rs145556679 (triglycerides levels beta −1.13 (SE 0.17), P=2.53 × 10−11, EAF 0.013). Our findings add empirical support to the contribution of low-frequency variants in complex traits, demonstrate the advantage of including population-specific sequences in imputation panels and exemplify the power gains afforded by population isolates.


bioRxiv | 2018

Cohort-wide deep whole genome sequencing and the allelic architecture of complex traits

Arthur Gilly; Daniel Suveges; Karoline Kuchenbaecker; Martin Pollard; Loz Southam; Konstantinos Hatzikotoulas; Aliki-Eleni Farmaki; Thea Bjornland; Ryan Waples; Emil Vr Appel; Elisabetta Casalone; Giorgio Melloni; Britt Kilian; Nigel W. Rayner; Ioanna Ntalla; Kousik Kundu; Klaudia Walter; John Danesh; Adam S. Butterworth; Inês Barroso; Emmanouil Tsafantakis; George Dedoussis; Ida Moltke; Eleftheria Zeggini

The role of rare variants in complex traits remains uncharted. Here, we conduct deep whole genome sequencing of 1,457 individuals from an isolated population, and test for rare variant burdens across six cardiometabolic traits. We identify a role for rare regulatory variation, which has hitherto been missed. We find evidence of rare variant burdens overlapping with, and mostly independent of established common variant signals (ADIPOQ and adiponectin, P=4.2×10−8; APOC3 and triglyceride levels, P=1.58×10−26; GGT1 and gamma-glutamyltransferase, P=2.3×10−6; UGT1A9 and bilirubin, P=1.9×10−8), and identify replicating evidence for a burden associated with triglyceride levels in FAM189A (P=2.26×10−8), indicating a role for this gene in lipid metabolism.


Nature Genetics | 2018

Author Correction: Discovery and refinement of genetic loci associated with cardiometabolic risk using dense imputation maps

Valentina Iotchkova; Jie Huang; John A. Morris; Deepti Jain; Caterina Barbieri; Klaudia Walter; Josine L. Min; Lu Chen; William Astle; Massimilian Cocca; Patrick Deelen; Heather Elding; Aliki-Eleni Farmaki; Christopher S. Franklin; Tom R. Gaunt; Albert Hofman; Tao Jiang; Marcus E. Kleber; Genevieve Lachance; Jian'an Luan; Giovanni Malerba; Angela Matchan; Daniel Mead; Yasin Memari; Ioanna Ntalla; Kalliope Panoutsopoulou; Raha Pazoki; John Perry; Fernando Rivadeneira; Maria Sabater-Lleal

In the version of the article published, the surname of author Aaron Isaacs is misspelled as Issacs.


European Respiratory Journal | 2018

The vitamin D binding protein axis modifies disease severity in Lymphangioleiomyomatosis

Suzanne Miller; Clare Coveney; Janice Johnson; Aliki-Eleni Farmaki; Nishant Gupta; Martin D. Tobin; Louise V. Wain; Francis X. McCormack; David J. Boocock; Simon R. Johnson

Lymphangioleiomyomatosis (LAM) is a rare disease of women. Decline in lung function is variable, making appropriate targeting of therapy difficult. We used unbiased serum proteomics to identify markers associated with outcome in LAM. 101 women with LAM and 22 healthy controls were recruited from the National Centre for LAM in the UK. 152 DNA and serum samples with linked lung function and outcome data were obtained from patients in the National Heart, Lung and Blood Institute LAM Registry in the USA. Proteomic analysis was performed on a discovery cohort of 50 LAM and 20 control serum samples using a SCIEX SWATH mass spectrometric workflow. Protein levels were quantitated by ELISA and single nucleotide polymorphisms in GC (group-specific component) encoding vitamin D binding protein (VTDB) were genotyped. Proteomic analysis showed VTDB was 2.6-fold lower in LAM than controls. Serum VTDB was lower in progressive compared with stable LAM (p=0.001) and correlated with diffusing capacity of the lung for carbon monoxide (p=0.01). Median time to death or lung transplant was reduced by 46 months in those with CC genotypes at rs4588 and 38 months in those with non-A-containing haplotypes at rs7041/4588 (p=0.014 and 0.008, respectively). The VTDB axis is associated with disease severity and outcome, and GC genotype could help predict transplant-free survival in LAM. The vitamin D binding protein and GC genotype are associated with lung function and survival in women with LAM http://ow.ly/UacI30leLzr


bioRxiv | 2017

Very low depth whole genome sequencing in complex trait association studies

Arthur Gilly; Karoline Kuchenbaecker; Lorraine Southam; Daniel Suveges; Rachel Moore; Giorgio E. M. Melloni; Konstantinos Hatzikotoulas; Aliki-Eleni Farmaki; Graham R. S. Ritchie; Jeremy Schwartzentruber; Petr Danecek; Britt Kilian; Martin Pollard; Xiangyu Ge; Heather Elding; William Astle; Tao Jiang; Adam S. Butterworth; Nicole Soranzo; Emmanouil Tsafantakis; Maria Karaleftheri; George Dedoussis; Eleftheria Zeggini

Motivation Very low depth sequencing has been proposed as a cost-effective approach to capture low-frequency and rare variation in complex trait association studies. However, a full characterisation of the genotype quality and association power for very low depth sequencing designs is still lacking. Results We perform cohort-wide whole genome sequencing (WGS) at low depth in 1,239 individuals (990 at 1x depth and 249 at 4x depth) from an isolated population, and establish a robust pipeline for calling and imputing very low depth WGS genotypes from standard bioinformatics tools. Using genotyping chip, whole-exome sequencing (WES, 75x depth) and high-depth (22x) WGS data in the same samples, we examine in detail the sensitivity of this approach, and show that imputed 1x WGS recapitulates 95.2% of variants found by imputed GWAS with an average minor allele concordance of 97% for common and low-frequency variants. In our study, 1x further allowed the discovery of 140,844 true low-frequency variants with 73% genotype concordance when compared to high-depth WGS data. Finally, using association results for 57 quantitative traits, we show that very low depth WGS is an efficient alternative to imputed GWAS chip designs, allowing the discovery of up to twice as many true association signals than the classical imputed GWAS design. Supplementary Data Supplementary Data are appended to this manuscript.

Collaboration


Dive into the Aliki-Eleni Farmaki's collaboration.

Top Co-Authors

Avatar

Angela Matchan

Wellcome Trust Sanger Institute

View shared research outputs
Top Co-Authors

Avatar

Lorraine Southam

Wellcome Trust Sanger Institute

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Arthur Gilly

Wellcome Trust Sanger Institute

View shared research outputs
Top Co-Authors

Avatar

Eleftheria Zeggini

Wellcome Trust Sanger Institute

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Graham R. S. Ritchie

Wellcome Trust Sanger Institute

View shared research outputs
Top Co-Authors

Avatar

Ioanna Ntalla

Queen Mary University of London

View shared research outputs
Top Co-Authors

Avatar

Ioanna Tachmazidou

Wellcome Trust Sanger Institute

View shared research outputs
Top Co-Authors

Avatar

Kalliope Panoutsopoulou

Wellcome Trust Sanger Institute

View shared research outputs
Researchain Logo
Decentralizing Knowledge